Why do you have neurotoxicity after breast cancer?
chemotherapy has a significant place in anti-oncological treatment, which causes neurological changes in the surroundings (chemotherapy-induced peripheral neuropathy, CIPN) is a series of neurofunctional disorders and signs of neurological damage to the surroundings or autonomous neuropsychiatrics. Of these, 30%-40% of the patients had neurological disorders in the surroundings, and the incidence of breast cancer was 11% ~ 80%, with a severe impact on their quality of life. Some patients are affected by CIPN reduction and even termination of treatment, which affects the efficacy of treatment. 1. What are the common chemotherapy drugs that can lead to CIPN? (1) vivigias: vivigiol, venomol lipids, doscitra, pheasant conjunctol, with a prevalence rate of 60-70% (2) platinum: e.g. carpenter, sauperium with an incidence rate of 40-70% (3) chromium: chronium, with an incidence rate of about 25% (4) Etidron: an incidence of about 85.4% ii, what is the expression of CIPN ‘ s neurotoxicity in the surroundings due to breast cancer chemotherapy, which is the most common among the neurological changes that occur in the neurologicallytic areas, according to the neurological differences of stress. SPN is represented by an abnormally symmetrical feeling of a pair of hands and feet (smudge, sting, burning), a change in the “sweet-sweed” sample, a sensory cosmosis disorder, a loss of vibration and joint position, representative of the platinum, vibratoria; MPN is represented by far-off physical incompetence, balance disorder, loss of fine motion, influence grip, etc., and APN is rarely expressed as constipated or diarrhoea, sweaty or sweatless, and low blood pressure stun. If a disease under treatment in the long spring is prone to abdominal pain and constipation, and in rare cases can cause paralysing enteric infarction, or even mental effects such as emotional instability, panic, stress, etc. of the patient, the serious can delay, reduce the amount of the drug used, or even put an end to chemotherapy [3]. CIPN, which is a result of violet and platinum, may occur acutely during chemotherapy, with severe symptoms that reduce the dose of chemotherapy or stop chemotherapy, affecting its efficacy. The neuropathic changes caused by the vivigial drugs usually improve after a few months, although the symptoms can improve over time, more than 30 per cent of the patients can develop into long-term, continuous CIPN, continue to suffer from their symptoms, affect the quality of life, lead to pacifism, and increase the risk of falling.
Common breast cancer chemotherapy drugs: violet — milder than platinum, lower limbs more severe than upper limbs, painful feeling abnormal, occasional small muscle weakness in the foot, high dose leading to absic and muscular disease, weak reflection, lower and rarer than violol in Dossitra; platinum — symmetrical, limbal and “moderation of gloves and socks”, pain plaster, rare, reflective and sensory diminished, rare ear, ear virulent; long spring alkali — lower limbs far-end feeling lost, less affecting upper limbs, generally limited to thorium reflect disappearing, with little to the less common, lower limb proximate impotence to step down, to reflect early reduction or loss, to reflect and abdominal arrhythmia, to see low blood pressure.
Breast cancer
